Evans syndrome
MONDO:0016030Evans syndrome is a rare chronic hematologic disorder characterized by the simultaneous or sequential association of autoimmune hemolytic anemia (AIHA; a disorder in which auto-antibodies are directed against red blood cells causing anemia of varying degrees of severity) with immune thrombocytopenic purpura (ITP; a coagulation disorder in which auto-antibodies are directed against platelets causing hemorrhagic episodes) and occasionally autoimmune neutropenia, in the absence of a known underlying etiology.
Also known as: Evans' syndrome, autoimmune hemolytic anaemia and autoimmune thrombocytopenia, autoimmune hemolytic anemia and autoimmune thrombocytopenia, immune pancytopenia, Evan syndrome
64 clinical trials for this condition and its sub-types, 19 tagged with Evans syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Cheap drug combo may tame tough anemia
Disease control CancelledThis trial tests a combination of two drugs, sirolimus and all-trans retinoic acid (ATRA), for people with autoimmune anemia that has not responded to standard treatments. Autoimmune anemia occurs when the immune system attacks red blood cells, causing fatigue and other symptoms.…
Phase 4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control CancelledThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC